Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
As H5N1 avian influenza continues circulating in U.S. dairy herds and poultry flocks — with over 70 confirmed human cases since 2024 — vaccine development has accelerated dramatically. Multiple candidates are now in human trials, and the FDA has granted fast track designation to an mRNA candidate. Here is a complete guide to where things stand in July 2026.
The H5N1 clade 2.3.4.4b virus has rewritten the playbook on avian influenza. Since March 2024, it has spread to over 940 dairy herds across 30+ states, decimated poultry flocks driving egg prices to record highs, and jumped to mammals including cats, raccoons, and marine life. While current human-to-human transmission remains absent, the virus's unprecedented mammalian host range has pandemic preparedness experts on high alert.
The good news: vaccine science has advanced enormously since the last major H5N1 scare in the mid-2000s. mRNA technology, refined during COVID-19, now offers a rapid-response platform that can produce updated vaccines within weeks of a strain change. And traditional approaches have also matured, with adjuvanted vaccines already stockpiled and ready for deployment.
Moderna mRNA-1018 entered Phase 2/3 trials in mid-2025 with approximately 6,000 participants. Early data shows strong neutralizing antibody responses after a single dose. Moderna can update the antigen sequence and begin manufacturing within 60 days of a strain change — a critical advantage if the virus mutates.
Arcturus Therapeutics ARCT-2304 received FDA fast track designation in January 2026. This self-amplifying mRNA (saRNA) vaccine is in Phase 1 human trials, targeting high-risk groups like poultry workers and older adults. The self-amplifying technology means lower doses may produce equivalent immune responses, potentially stretching supply further during a pandemic.
A breakthrough nasal spray H5N1 vaccine developed using an influenza virus vector platform showed strong protection in animal tests in early 2026, outperforming traditional injected flu shots. Published in February 2026, the research demonstrated that nasal delivery may provide superior mucosal immunity — blocking the virus at its point of entry in the respiratory tract, rather than just preventing severe disease.
Separately, researchers at the University of Nebraska–Lincoln published results in April 2026 showing a novel vaccine approach that protected both mice and dairy calves against severe H5N1 disease. The team is seeking funding for a multispecies vaccine that could simultaneously protect humans and livestock — addressing both the public health and agricultural dimensions of the outbreak.
CSL Seqirus maintains the most deployment-ready position. Their MF59-adjuvanted, cell-based H5N1 vaccine already has FDA pre-pandemic approval and approximately 10 million doses are stockpiled in the Strategic National Stockpile. These could be deployed within weeks of a pandemic declaration without needing new authorization.
Sanofi is developing a recombinant protein-based candidate using its FluBlok platform, with Phase 1/2 data showing strong antibody responses with adjuvant. GSK has an AS03-adjuvanted H5N1 vaccine under contract with BARDA.
The FDA's fast track designation for ARCT-2304 signals regulatory urgency. Fast track allows more frequent FDA meetings, rolling review of data (rather than waiting for a complete package), and potential priority review — cutting months off the typical approval timeline.
Additionally, the FDA's pre-pandemic approval pathway lets vaccines be manufactured and stockpiled based on immunogenicity data (immune response) rather than real-world efficacy trials, which can't be conducted before a pandemic starts. This is how CSL Seqirus' vaccine was approved and stockpiled.
In a significant development for vaccine safety transparency, the CDC and FDA expanded public access to VAERS data in May 2025 through the WONDER database and downloadable files. This enhancement provides more complete reporting on all adverse events following vaccination, including expanded secondary report data. For any future H5N1 vaccine, VAERS monitoring would follow the enhanced framework established during COVID-19, including the Vaccine Safety Datalink (VSD) and V-safe for active surveillance.
The timeline depends on whether H5N1 begins sustained human-to-human transmission:
While waiting for an H5N1 vaccine, public health agencies recommend:
Bird flu vaccine development in 2026 is further advanced than at any previous point in history. mRNA candidates are in human trials, nasal spray vaccines show promise in animal studies, and millions of doses are already stockpiled for emergency use. The FDA's fast track designation and the expanded VAERS monitoring infrastructure mean that when an H5N1 vaccine does reach the public, both the speed of deployment and the rigor of safety surveillance will be unprecedented. VaccineWatch will track all H5N1 vaccine VAERS data as it becomes available.